Compounds Studied in Sleep and Circadian Research

Research Studies

DSIP and circadian rhythm regulation

Delta sleep-inducing peptide (DSIP) is a nonapeptide first isolated from rabbit cerebral venous blood. In the catalogue it is supplied as a lyophilised powder for laboratory use. Research interest centres on its reported association with slow-wave sleep architecture and its modulation of circadian entrainment pathways. Preclinical work has examined its effects on EEG delta power and on the hypothalamic-pituitary-adrenal axis, though the evidence base remains largely animal-derived. No human dosing or clinical outcome is implied by these observations.

Epithalon (Epitalon) and pineal regulation of circadian timing

Epithalon (Epitalon) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from the pineal peptide preparation epithalamine. It has been studied in the context of pineal gland function and melatonin rhythm regulation, with research models examining its influence on circadian periodicity and telomerase-related endpoints in cell culture. The compound is not approved for human therapeutic use, and all findings to date are from preclinical or in vitro systems.

CJC-1295 with DAC and GH axis modulation during sleep

CJC-1295 with DAC is a growth hormone-releasing hormone (GHRH) analogue modified with a drug affinity complex to extend its half-life. Research has focused on its ability to stimulate pulsatile GH release, which is tightly coupled to slow-wave sleep onset. Studies in animal models have explored whether sustained GHRH receptor activation alters sleep architecture, particularly delta wave activity. The compound is supplied for research purposes only; no human dosing or sleep-related outcome is claimed.

Cerebrolysin and neurotrophic support in sleep-related models

Cerebrolysin is a porcine brain-derived peptide preparation containing neurotrophic factors. It has been investigated in preclinical models of neurodegenerative disease and, to a lesser extent, in studies of sleep-wake regulation and neuronal plasticity. Some animal work suggests effects on REM sleep duration, but the mechanism remains unclear and human data are limited. The product is sold strictly for laboratory research.

BPC-157 and recovery from sleep disruption in musculoskeletal models

BPC-157 is a synthetic pentadecapeptide derived from a gastric protein. While its primary research focus is on tendon and ligament healing, some studies have examined its impact on recovery from sleep deprivation in animal models, particularly regarding inflammatory cytokine profiles. A clinical trial is currently investigating its effects on tendon healing after rotator cuff repair [7], but no sleep-specific human data exist. This compound is not for human consumption.

ARA-290 and innate repair mechanisms in circadian stress models

ARA-290 is an 11-amino acid peptide derived from erythropoietin, acting on the innate repair receptor. Research has explored its tissue-protective effects in models of metabolic and inflammatory stress, including those induced by circadian disruption. No studies have directly assessed sleep outcomes in humans. The compound is provided for research use only.

5-Amino-1MQ and metabolic regulation in sleep-related metabolic studies

5-Amino-1MQ is a small molecule inhibitor of nicotinamide N-methyltransferase (NNMT). It has been studied in the context of metabolic regulation, including models of diet-induced obesity and insulin resistance, which are often comorbid with sleep disorders. Some preclinical work suggests effects on energy expenditure and fat oxidation, but no direct sleep research has been published. This product is intended for laboratory research only.

Adipotide and adipose tissue effects in sleep apnea models

Adipotide is a peptidomimetic that targets prohibitin on the vasculature of white adipose tissue, inducing apoptosis. Research has examined its effects on fat mass reduction in animal models of obesity, a condition frequently associated with obstructive sleep apnea. However, no studies have directly measured sleep apnea outcomes. The compound is not approved for human use and is sold for research purposes only.

AOD9604 (Fragment 176-191) and lipid metabolism in sleep-related metabolic research

AOD9604 is a modified fragment of human growth hormone (residues 176-191) that has been studied for its lipolytic activity in animal models. While its primary research focus is on fat metabolism, some investigations have explored its impact on metabolic parameters relevant to sleep disorders such as obesity and insulin resistance. No human sleep data are available. This product is for research use only.

Bacteriostatic water and its role in laboratory research

Bacteriostatic water is sterile water containing 0.9% benzyl alcohol, used as a diluent for reconstituting lyophilised peptides in laboratory settings. It is not a therapeutic agent and has no direct role in sleep or circadian research beyond its use as a solvent. It is supplied for research purposes only.

BPC-157 + TB-500 blend and combined regenerative approaches in sleep research

The BPC-157 + TB-500 blend combines two synthetic peptides studied for their regenerative and anti-inflammatory properties. While neither has been directly investigated for sleep effects, some preclinical models of sleep deprivation have examined similar compounds for their ability to modulate recovery processes. No human data exist for this blend. It is sold strictly for laboratory research.

Cagrilintide and amylin receptor signalling in metabolic-sleep interactions

Cagrilintide is a long-acting amylin analogue. Research has focused on its effects on satiety and glucose control, with some studies examining metabolic parameters that overlap with sleep regulation, such as nocturnal glucose variability. No direct sleep studies have been published. This compound is for research use only.

If you are reading this for personal health reasons

The compounds described here are sold exclusively for laboratory research. We do not provide dosing, medical guidance, or any suggestion that these materials are suitable for human use. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

• [1] AI-assisted Subtyping-directed Precision Treatment in Acute Aortic Dissection. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT07382375
• [2] Postpartum Semaglutide to Reduce Cardiometabolic Risk After Gestational Diabetes. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT07797036
• [3] Nicotinamide for Retinal Protection in Primary Open-Angle Glaucoma (NADIR Trial). ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT07808333
• [4] Mitophagy and Mitochondrial DNA Dynamics During Ramadan Dry Fasting vs 16:8 Time-Restricted Feeding. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT07638696
• [5] Preoperative Optimization With Tirzepatide, Ketogenic Diet, or Standard Care Before One Anastomosis Gastric Bypass Surgery. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT07622992
• [6] Two-Part Study of the Effects of the X39 Patch on Circulating GHK and GHK-Cu Levels in Healthy Adults. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT07706361
• [7] Impact of BPC-157 on Recovery Following Rotator Cuff Repair Surgery. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT07803250
• [8] GLP-1/GIP Receptor Agonists in Obesity-Related HFpEF: The GLIDE-HF Registry. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT07787936
• [9] Efficacy and Safety of Semaglutide Versus Placebo on Cardiometabolic Profile in Patients With Schizophrenia With Metabolic Syndrome. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT07770282
• [10] HMB Plus Vitamin D to Preserve Muscle in Older Adults Starting Semaglutide. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT07760948
• [11] The NICE-PAD II Trial. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT07782671
• [12] A Study of SYH2069 Injection in Participants With T2DM Not Controlled With Diet/Exercise Alone or Metformin. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT07796477